Download Free Cancer Registry Management Book in PDF and EPUB Free Download. You can read online Cancer Registry Management and write the review.

If you are a member of NCRA and would like to receive member discount pricing on this item, please contact customer service at 800-228-0810. Discounted orders cannot be processed via the website.
This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews.
Data obtained by population based cancer registries have a pivotal role in cancer control. Now also available in Spanish and French, this volume, which contains 15 authored chapters and four useful appendices, remains a standard reference for those planning to establish new cancer registries and those keen to adopt recognized methodologies. Information is given on the techniques required to collect, store, analyse and interpret data.
The book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism. However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited. This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requring metabolic solutions for its management and prevention. Support for this position is derived from critical assessment of current cancer theories. Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate.
The Cancer in Sub-Saharan Africa volume brings together population-based cancer incidence data from 25 cancer registries in 20 sub-Saharan African countries that are part of the African Cancer Registry Network. The compiled data in this volume, presented and commented upon by covered population and by anatomical site, are of tremendous value to the assessment of the pattern and evolution of cancer in Africa, as a means of elucidating, confirming, and evaluating causes of the disease.
Breast Cancer: A New Era in Management provides a compendium of succinct analysis of the many facets involved in the present day management of the breast cancer patient. The text provides the clinician or student with basic foundational knowledge in the rapidly expanding areas of expertise that are required for both the diagnosis and treatment of the breast cancer patient. Each topic, whether diagnostic or therapeutic, is presented in a straightforward fashion incorporating as part of each topic a description of the historical clinical landmarks leading to the present day, their present day position in the care of the breast patient, and finally, an assessment of possible future application and adaptation in clinical practice. Emphasis is placed on clear and concise explanations of each topic presented in stepwise fashion from fundamental elements to the more complex. Breast Cancer: A New Era in Management will act as a ready reference for the practicing surgeon and students seeking practical information on a particular clinical topic or scenario.
Early recognition and management of adverse effects of cancer treatments are essential for optimal care of patients with cancer, and drastically different approaches are required for different physiologic reactions. Handbook of Cancer Treatment-Related Symptoms and Toxicities is a focused, one-stop resource that enables clinicians to quickly find up-to-date, reliable information needed at the point of care. The high-yield approach prioritizes the most common toxicities associated with cancer treatment, and concise, templated chapters offer fast access to information needed in day-to-day practice. - Presents a user-friendly overview of cancer treatment-related symptoms and toxicities management in a practical, easy-to-use format, allowing you to quickly find information in one convenient, concise resource. - Covers systemic and radiation therapies, including chemotherapy, immunotherapy, targeted therapies, and radiation therapy, detailing symptoms of each toxicity to confirm your diagnosis. - Overviews pharmacologic and non-pharmacologic approaches to symptom management. - Offers recommendations for mitigating toxicities in high-risk patients. - Discusses key topics such as management of infusion reactions, when the need for biopsy is warranted, and the unique challenges posed by novel immunotherapies.